Mrs Valeria Starr, LCSW, CADC, GC-C | |
5000 S 5th Ave, Bldg 228, 4north, Hines, IL 60141-3030 | |
(708) 202-8387 | |
Not Available |
Full Name | Mrs Valeria Starr |
---|---|
Gender | Female |
Speciality | Social Worker - Clinical |
Location | 5000 S 5th Ave, Hines, Illinois |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1740668854 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
101YA0400X | Counselor - Addiction (substance Use Disorder) | 31240 (Illinois) | Secondary |
1041C0700X | Social Worker - Clinical | 149.017902 (Illinois) | Primary |
Mailing Address | Practice Location Address |
---|---|
Mrs Valeria Starr, LCSW, CADC, GC-C 5000 S 5th Ave, Hines, IL 60141-3030 Ph: (708) 202-4960 | Mrs Valeria Starr, LCSW, CADC, GC-C 5000 S 5th Ave, Bldg 228, 4north, Hines, IL 60141-3030 Ph: (708) 202-8387 |
News Archive
The Almac Group, one of the world's leading contract drug development and manufacturing organisations, was presented with the "News Flow of the Year" accolade at the 2010 Genesis Awards annual Gala dinner in London last week, following the company being shortlisted as a finalist in the category nominations. Now into its tenth year, Genesis is established as a leading life science networking conference.
For a patient with sepsis - which kills more Americans every year than AIDS and breast and prostate cancer combined - hours can make the difference between life and death.
With less than two weeks to go in open enrollment, analysts size up the likelihood of reaching signup targets for young people and worry about the impact of that and other factors on 2015 premiums for exchange plans. The role of insurance brokers is also examined.
Covagen and Tanabe Research Laboratories U.S.A, Inc., a fully owned subsidiary of Mitsubishi Tanabe Pharma Corporation, today announced that they expanded their strategic research collaboration. MTPC and TRL have nominated a first bispecific FynomAb for formal preclinical development which triggered an undisclosed milestone payment. MTPC and TRL also exercised an option for a second bispecific FynomAb program based on the parties' research and licensing agreement signed in October 2012.
› Verified 6 days ago